Skip to content

Phase II clinical study of pemetrexed combined with lenalidomide in the treatment of relapsed/refractory primary central nervous system lymphoma

Phase II clinical study of pemetrexed combined with lenalidomide in the treatment of relapsed/refractory primary central nervous system lymphoma

Status
Recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028070
Enrollment
Unknown
Registered
2019-12-10
Start date
2018-06-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

Sponsors

Huashan Hospital North, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-75 years; 2. the first symptom of the subject was damage to the central nervous system or eyes, and the lesion was confined to the central nervous system or eyes; 3. non-hodgkin's lymphoma was confirmed by histopathology and immunohistochemistry; 4. no systemic involvement of lymphatic hematopoietic tissues or other systems was found by rigorous physical examination and auxiliary examination; 5. assessment of disease progression or recurrence after total cranial radiotherapy and two or more regiments-including high-dose methotrexate-based regiments-after chemotherapy.

Exclusion criteria

Exclusion criteria: 1. female pregnancy; 2. no pathological examination confirmed lymphoma; 3. the tumor involves other parts of the central nervous system; 4. severe cardiac, liver or renal insufficiency; 5. allergy or contraindication to any drug involved in the program; 6. he also suffers from malignant tumors of other organs; 7. active stage of patients with HAV, HBV, HCV and tuberculosis, and hiv-positive patients; 8. inability to understand or follow research protocols.

Design outcomes

Primary

MeasureTime frame
CR;

Countries

China

Contacts

Public ContactBobin Chen

Huashan Hospital North, Fudan University

bbchen@fudan.edu.cn+86 13402186236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026